Bespoke Extracts (BSPK) Return on Capital Employed (2012 - 2025)
Bespoke Extracts (BSPK) reported Return on Capital Employed of 40.24% for Q3 2025, down 3834.0% on a YoY basis from 1.08% in Q3 2024, and down 41.8% sequentially from 69.13% in Q2 2025.
Bespoke Extracts (BSPK) Return on Capital Employed (2012 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 14 years of Return on Capital Employed data on file, last reported at 40.24% in Q3 2025.
- For the quarter ending Q3 2025, Return on Capital Employed fell 3834.0% year-over-year to 40.24%; the trailing twelve-month figure through Sep 2025 stood at 40.24% (down 3834.0% YoY), and the FY2024 full-year result was 130.54%, down 8066.0% from the prior year.
- Return on Capital Employed slipped to 40.24% in Q3 2025, from 69.13% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4328.7% in Q2 2021 to a low of 4491.33% in Q4 2021.
- A 5-year average of 630.37% and a median of 207.99% in 2023 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 341464 bps in 2021, while the deepest fall reached 540872 bps in 2021.
- Tracing BSPK's Return on Capital Employed over 5 years: stood at 4491.33% in 2021, then jumped by 119 bps to 844.61% in 2022, then sank by 75 bps to 207.99% in 2023, then tumbled by 38 bps to 129.15% in 2024, then tumbled by 69 bps to 40.24% in 2025.
- Business Quant data shows BSPK's Return on Capital Employed at 40.24% in Q3 2025, 69.13% in Q2 2025, and 99.92% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 40.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.24% |
| Jun 30, 2025 | 69.13% |
| Mar 31, 2025 | 99.92% |
| Dec 31, 2024 | 129.15% |
| Sep 30, 2024 | 78.57% |
| Jun 30, 2024 | 91.94% |
| Mar 31, 2024 | 134.46% |
| Dec 31, 2023 | 207.99% |
| Sep 30, 2023 | 415.76% |
| Jun 30, 2023 | 999.98% |
| Mar 31, 2023 | 433.79% |
| Dec 31, 2022 | 844.61% |
| Sep 30, 2022 | 2,413.99% |
| Jun 30, 2022 | 545.77% |
| Mar 31, 2022 | 3,066.13% |
| Nov 30, 2021 | -4,491.33% |
| Aug 31, 2021 | -646.01% |
| May 31, 2021 | 4,328.70% |
| Feb 28, 2021 | 3,214.17% |
| Nov 30, 2020 | 917.38% |